Gate2Brain — Series A (estimated) · €7M

Blood-brain-barrier drug-delivery biotech (UB/IRB spin-off) secured €7M from strategic partner Shilpa Biocare (30.4% stake) — its largest raise to date — to advance G2B-002 for pediatric brain tumors.

Lead (est.) (estimated)Shilpa Biocare RoundSeries A (estimated) Announced16 Jun 2026 CityBarcelona SectorHealthtech & Bio Source E I P

Something wrong? Suggest a correction →